1. Home
  2. SQNS vs KPTI Comparison

SQNS vs KPTI Comparison

Compare SQNS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SQNS
  • KPTI
  • Stock Information
  • Founded
  • SQNS 2003
  • KPTI 2008
  • Country
  • SQNS France
  • KPTI United States
  • Employees
  • SQNS N/A
  • KPTI N/A
  • Industry
  • SQNS Semiconductors
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • SQNS Technology
  • KPTI Health Care
  • Exchange
  • SQNS Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • SQNS 85.7M
  • KPTI 81.1M
  • IPO Year
  • SQNS 2011
  • KPTI 2013
  • Fundamental
  • Price
  • SQNS $2.97
  • KPTI $0.62
  • Analyst Decision
  • SQNS Strong Buy
  • KPTI Strong Buy
  • Analyst Count
  • SQNS 1
  • KPTI 4
  • Target Price
  • SQNS $7.50
  • KPTI $5.00
  • AVG Volume (30 Days)
  • SQNS 107.6K
  • KPTI 679.6K
  • Earning Date
  • SQNS 02-11-2025
  • KPTI 02-27-2025
  • Dividend Yield
  • SQNS N/A
  • KPTI N/A
  • EPS Growth
  • SQNS N/A
  • KPTI N/A
  • EPS
  • SQNS 1.65
  • KPTI N/A
  • Revenue
  • SQNS $30,555,000.00
  • KPTI $148,442,000.00
  • Revenue This Year
  • SQNS $10.14
  • KPTI $5.47
  • Revenue Next Year
  • SQNS $8.54
  • KPTI $6.33
  • P/E Ratio
  • SQNS $1.90
  • KPTI N/A
  • Revenue Growth
  • SQNS N/A
  • KPTI 1.77
  • 52 Week Low
  • SQNS $0.85
  • KPTI $0.58
  • 52 Week High
  • SQNS $7.33
  • KPTI $1.70
  • Technical
  • Relative Strength Index (RSI)
  • SQNS 43.35
  • KPTI 41.95
  • Support Level
  • SQNS $3.00
  • KPTI $0.60
  • Resistance Level
  • SQNS $3.39
  • KPTI $0.69
  • Average True Range (ATR)
  • SQNS 0.22
  • KPTI 0.05
  • MACD
  • SQNS -0.03
  • KPTI -0.00
  • Stochastic Oscillator
  • SQNS 0.00
  • KPTI 18.17

About SQNS Sequans Communications S.A.

Sequans Communications SA is a designer, developer, and supplier of cellular semiconductor solutions for broadband Internet of Things (IoT) markets. Its solutions incorporate baseband processor and radio frequency, transceiver integrated circuits, along with its proprietary signal processing techniques, algorithms, and software stacks. The company's solutions serve as the core wireless broadband communications platform in devices, including smartphones, USB dongles, portable routers, laptops, netbooks, tablets, and other consumer multimedia and industrial devices. Its geographical segments are Taiwan, Korea, China (including Hong Kong), the Rest of Asia, the United States and the Rest of the world.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: